Through almost six months, 2010 has not been kind to many of the world’s largest companies, as a choppy market has given investors plenty of reasons to stay on the sidelines; debt issues threaten to drag down bank profits and a massive oil spill in the Gulf has sliced BP’s shares nearly in half since the spill began almost six weeks ago (weighing on the entire sector in the process). Meanwhile, an often overlooked situation is brewing at pharma giant Johnson & Johnson (JNJ), as the firm was recently forced to recall several children’s pain and cold medicines over manufacturing issues which may have put metal particles into the products. Since hitting its 2010 high of just over $66/share, JNJ has plummeted more than 11.2% to its current share price of roughly $58.6/share, and some believe that the worst could still be ahead for the pharmaceutical giant. [click to continue…]
{ Comments on this entry are closed }








